{"url":"https://newsforagent.com/news/2026-11-01/sai-parenterals-q2-profit-revenue-sp-analytics","markdown_url":"https://newsforagent.com/news/2026-11-01/sai-parenterals-q2-profit-revenue-sp-analytics.md","title":"Sai Parenterals Q2 Net Profit Up 65% to ₹105 Million","headline":"Sai Parenterals Q2 Net Profit Rises 65% as Revenue Jumps 264% and Board Approves SP Analytics Buyout","description":"Sai Parenterals posted a 65% rise in Q2 net profit to ₹105.10 million on revenue of ₹1,949.18 million.","section":"Earnings & Results","published_at":"2026-11-01T10:12:38+00:00","modified_at":"2026-11-01T10:12:38+00:00","author":"News Desk","key_takeaways":["Sai Parenterals reported consolidated net profit of ₹105.10 million for Q2FY27, up 65% year on year.","Revenue from operations rose 264% to ₹1,949.18 million from ₹535.28 million a year earlier.","The board approved acquiring the remaining 25% of SP Analytics for ₹25,000 across 2,500 equity shares, making it a wholly owned subsidiary."],"companies":[{"name":"Sai Parenterals","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0003fi8/sai-parenterals","website":"https://www.saiparenterals.com/home"}],"source":{"publisher":"ScanX","title":"Sai Parenterals Q2FY27 Results: Net profit up 65% YoY to ₹105 million","url":"https://scanx.trade/stock-market-news/companies/sai-parenterals-q2fy27-results-net-profit-up-65-yoy-105-million/55071223"},"other_sources":[],"tags":["Earnings & Results","Sai Parenterals"],"body_markdown":"[Sai Parenterals](https://akta.pro/company-profiles/0003fi8/sai-parenterals) reported a 65% year-on-year rise in consolidated net profit to ₹105.10 million for the quarter ended September 30, 2026, with revenue from operations up 264% to ₹1,949.18 million. [ScanX](https://scanx.trade/stock-market-news/companies/sai-parenterals-q2fy27-results-net-profit-up-65-yoy-105-million/55071223) published the results on November 1, 2026. The Hyderabad-based company makes branded generic formulations and runs a CDMO business across injectables, orals and cephalosporins for government agencies, pharmaceutical companies and export markets.\n\n## Sai Parenterals' Revenue and Profit Growth\n\nRevenue from operations climbed from ₹535.28 million in the same quarter last year. Total income rose to ₹1,986.37 million from ₹548.63 million, and profit before tax increased to ₹98.89 million from ₹91.54 million. Basic earnings per share rose to ₹2.38 from ₹0.48.\n\nCash and cash equivalents fell to ₹1,293.30 million from ₹4,169.66 million at the start of the half-year. Cash generated from operations was negative at ₹2,012.98 million, which the report attributes mainly to a ₹734.92 million increase in trade receivables and a ₹1,131.41 million decrease in other financial liabilities.\n\n## SP Analytics Stake and Saicriti Pharma Deal\n\nThe board approved the acquisition of the remaining 25% equity shareholding in SP Analytics Private Limited, a subsidiary in which Sai Parenterals already held 75%. The transaction is valued at ₹25,000 for 2,500 equity shares and will make SP Analytics a wholly owned subsidiary. SP Analytics was incorporated in November 2023 and reported nil turnover over the last three financial years.\n\nThe board also noted the completion of the acquisition of 60% of the equity share capital of Saicriti Pharma Private Limited, which has become a subsidiary. A Management Committee chaired by Managing Director Anil Kumar Karusala was constituted to oversee administration.\n\n## Sai Parenterals' Listing and Noumed Stake\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Sai Parenterals listed on the NSE and BSE on April 2, 2026 under ticker SAIPARENT (BSE: 544742), with shares debuting at a 2-3% premium to the ₹392 issue price. The company completed its IPO in March 2026, raising ₹408.79 crore through a ₹285 crore fresh issue and a ₹123.79 crore offer for sale. In November 2025 it acquired a 74.6% equity stake in Australian pharmaceutical company Noumed Pharmaceuticals Pty Ltd for ₹125 crore ($13.9 million).\n\n## Australian Contracts Before the Results\n\nIn August 2026, Sai Parenterals' subsidiary Noumed renewed an OTC supply agreement with an Australian pharmacy chain, raising the contract value to AUD 30 million (₹204 crore) over three years, Business Standard reported. CNBCTV18 reported that a three-year, AU$30 million supply agreement lifted the company's total contracted OTC commitments in Australia to AU$232 million, or about ₹1,506 crore. In July 2026, BusinessLine reported that Noumed renewed an exclusive OTC medicines supply agreement with an Australian pharmacy chain, expanding the portfolio and agreement value to ₹1,300 crore over 7.5 years.\n\n## Sai Parenterals' Investor Meeting Date\n\nSai Parenterals will hold an analyst and institutional investor meeting on October 14, 2026 at 11:00 am at its facilities in Hyderabad, according to a filing signed by Anil Kumar Karusala.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}